Organelle stress sensors and cell death mechanisms in neurodegenerative diseases

CNS and Neurological Disorders - Drug Targets

Volumn 9, Issue 6, 2010, Pages 679-692

  Viana, Ricardo J S ^a   Fonseca, Maria B ^a   Ramalho, Rita M ^a   Nunes, Ana F ^a   Rodrigues, Cecília M P ^a  

^a UNIVERSITY OF LISBON   (Portugal)

Author keywords

Apoptosis; cell death; cell signaling; neurodegeneration; neuroprotection; organelles; stress sensors

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; AVICIN; CALCIUM; CARNITINE; CHAPERONE; CREATINE; CYSTAMINE; DEATH RECEPTOR; DEFEROXAMINE; DIMEBON; DIZOCILPINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; MELATONIN; MINOCYCLINE; NICOTINAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; PROTEINASE; RESVERATROL; RILUZOLE; ROSIGLITAZONE; SALUBRINAL; SIRTUIN; TACROLIMUS; TAUROURSODEOXYCHOLIC ACID; THIOCTIC ACID; TRITERPENE DERIVATIVE; UBIDECARENONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; ARTICLE; CALCIUM TRANSPORT; CELL DEATH; CELL MEMBRANE; CELL NUCLEUS; CELL ORGANELLE; CELL STRESS; CYTOSKELETON; DEGENERATIVE DISEASE; DNA DAMAGE; ENDOPLASMIC RETICULUM; GENE EXPRESSION; GOLGI COMPLEX; HOMEOSTASIS; HUMAN; LYSOSOME; MITOCHONDRIAL PERMEABILITY; MITOCHONDRION; NERVE CELL NECROSIS; NONHUMAN; SENSOR;

EID: 78649287483     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152710793237511     Document Type: Article

References (200)

1. Vila, M.; Przedborski, S. Targeting programmed cell death in neurodegenerative diseases. Nat. Rev. Neurosci., 2003, 4, 365-375.
2. Kroemer, G.; Galluzzi, L.; Vandenabeele, P.; Abrams, J.; Alnemri, E.S.; Baehrecke, E.H.; Blagosklonny, M.V.; El-Deiry, W.S.; Golstein, P.; Green, D.R.; Hengartner, M.; Knight, R.A.; Kumar, S.; Lipton, S.A.; Malorni, W.; Nunez, G.; Peter, M.E.; Tschopp, J.; Yuan, J.; Piacentini, M.; Zhivotovsky, B.; Melino, G. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ., 2009, 16, 3-11.
3. Galluzzi, L.; Aaronson, S.A.; Abrams, J.; Alnemri, E.S.; Andrews, D.W.; Baehrecke, E.H.; Bazan, N.G.; Blagosklonny, M.V.; Blomgren, K.; Borner, C.; Bredesen, D.E.; Brenner, C.; Castedo, M.; Cidlowski, J.A.; Ciechanover, A.; Cohen, G.M.; De Laurenzi, V.; De Maria, R.; Deshmukh, M.; Dynlacht, B.D.; El-Deiry, W.S.; Flavell, R.A.; Fulda, S.; Garrido, C.; Golstein, P.; Gougeon, M.L.; Green, D.R.; Gronemeyer, H.; Hajnoczky, G.; Hardwick, J.M.; Hengartner, M.O.; Ichijo, H.; Jaattela, M.; Kepp, O.; Kimchi, A.; Klionsky, D.J.; Knight, R.A.; Kornbluth, S.; Kumar, S.; Levine, B.; Lipton, S.A.; Lugli, E.; Madeo, F.; Malomi, W.; Marine, J.C.; Martin, S.J.; Medema, J.P.; Mehlen, P.; Melino, G.; Moll, U.M.; Morselli, E.; Nagata, S.; Nicholson, D.W.; Nicotera, P.; Nunez, G.; Oren, M.; Penninger, J.; Pervaiz, S.; Peter, M.E.; Piacentini, M.; Prehn, J.H.; Puthalakath, H.; Rabinovich, G.A.; Rizzuto, R.; Rodrigues, C.M.; Rubinsztein, D.C.; Rudel, T.; Scorrano, L.; Simon, H.U.; Steller, H.; Tschopp, J.; Tsujimoto, Y.; Vandenabeele, P.; Vitale, I.; Vousden, K.H.; Youle, R.J.; Yuan, J.; Zhivotovsky, B.; Kroemer, G. Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ., 2009, 16, 1093-1107.
4. Mohseni, N.; McMillan, S.C.; Chaudhary, R.; Mok, J.; Reed, B.H. Autophagy promotes caspase-dependent cell death during Drosophila development. Autophagy, 2009, 5, 329-338.
5. Maiuri, M.C.; Zalckvar, E.; Kimchi, A.; Kroemer, G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat. Rev. Mol. Cell Biol., 2007, 8, 741-752.
6. Galluzzi, L.; Vicencio, J.M.; Kepp, O.; Tasdemir, E.; Maiuri, M.C.; Kroemer, G. To die or not to die: that is the autophagic question. Curr. Mol. Med., 2008, 8, 78-91.
7. Bredesen, D.E.; Rao, R.V.; Mehlen, P. Cell death in the nervous system. Nature, 2006, 443, 796-802.
8. Kerr, J.F.; Wyllie, A.H.; Currie, A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer, 1972, 26, 239-257.
9. Fadok, V.A.; Voelker, D.R.; Campbell, P.A.; Cohen, J.J.; Bratton, D.L.; Henson, P.M. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J. Immunol., 1992, 148, 2207-2216.
10. Martin, S.J.; Finucane, D.M.; Amarante-Mendes, G.P.; O'Brien, G.A.; Green, D.R. Phosphatidylserine externalization during CD95-induced apoptosis of cells and cytoplasts requires ICE/CED- 3 protease activity. J. Biol. Chem., 1996, 271, 28753-28756.
11. Hamon, Y.; Broccardo, C.; Chambenoit, O.; Luciani, M.F.; Toti, F.; Chaslin, S.; Freyssinet, J.M.; Devaux, P.F.; McNeish, J.; Marguet, D.; Chimini, G. ABC1 promotes engulfment of apoptotic cells and transbilayer redistribution of phosphatidylserine. Nat. Cell Biol., 2000, 2, 399-406.
12. Fadok, V.A.; Bratton, D.L.; Rose, D.M.; Pearson, A.; Ezekewitz, R.A.; Henson, P.M. A receptor for phosphatidylserine-specific clearance of apoptotic cells. Neurotrophins and neurodegeneration. Nature, 2000, 405, 85-90.
13. Dawbarn, D.; Allen, S.J. Neurotrophins and neurodegeneration. Neuropathol. Appl. Neurobiol., 2003, 29, 211-230.
14. Mattson, M.P.; Magnus, T. Ageing and neuronal vulnerability. Nat. Rev. Neurosci., 2006, 7, 278-294.
15. Ferrer, I.; Marin, C.; Rey, M.J.; Ribalta, T.; Goutan, E.; Blanco, R.; Tolosa, E.; Marti, E. BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies. J. Neuropathol. Exp. Neurol., 1999, 58, 729-739.
16. Murray, K.D.; Gall, C.M.; Jones, E.G.; Isackson, P.J. Differential regulation of brain-derived neurotrophic factor and type II calcium/calmodulin-dependent protein kinase messenger RNA expression in Alzheimer's disease. Neuroscience, 1994, 60, 37-48.
17. Scott, S.A.; Crutcher, K.A. Nerve growth factor and Alzheimer's disease. Rev. Neurosci., 1994, 5, 179-211.
18. Scott, S.A.; Mufson, E.J.; Weingartner, J.A.; Skau, K.A.; Crutcher, K.A. Nerve growth factor in Alzheimer's disease: increased levels throughout the brain coupled with declines in nucleus basalis. J. Neurosci., 1995, 15, 6213-6221.
19. Bossers, K.; Meerhoff, G.; Balesar, R.; van Dongen, J.W.; Kruse, C.G.; Swaab, D.F.; Verhaagen, J. Analysis of gene expression in Parkinson's disease: possible involvement of neurotrophic support and axon guidance in dopaminergic cell death. Brain Pathol., 2009, 19, 91-107.
20. Zuccato, C.; Ciammola, A.; Rigamonti, D.; Leavitt, B.R.; Goffredo, D.; Conti, L.; MacDonald, M.E.; Friedlander, R.M.; Silani, V.; Hayden, M.R.; Timmusk, T.; Sipione, S.; Cattaneo, E. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science, 2001, 293, 493-498.
21. Kust, B.M.; Copray, J.C.; Brouwer, N.; Troost, D.; Boddeke, H.W. Elevated levels of neurotrophins in human biceps brachii tissue of amyotrophic lateral sclerosis. Exp. Neurol., 2002, 177, 419-427.
22. Mattson, M.P. Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders. Neuromol. Med., 2003, 3, 65-94.
23. Lipton, S.A. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr. Alzheimer Res., 2005, 2, 155-165.
24. Kress, G.J.; Reynolds, I.J. Dopaminergic neurotoxins require excitotoxic stimulation in organotypic cultures. Neurobiol. Dis., 2005, 20, 639-645.
25. Feany, M.B.; Pallanck, L.J. Parkin: a multipurpose neuroprotective agent? Neuron, 2003, 38, 13-16.
26. Aleyasin, H.; Rousseaux, M.W.; Phillips, M.; Kim, R.H.; Bland, R.J.; Callaghan, S.; Slack, R.S.; During, M.J.; Mak, T.W.; Park, D.S. The Parkinson's disease gene DJ-1 is also a key regulator of stroke-induced damage. Proc. Natl. Acad. Sci. USA, 2007, 104, 18748-18753.
27. Behrens, P.F.; Franz, P.; Woodman, B.; Lindenberg, K.S.; Landwehrmeyer, G.B. Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain, 2002, 125, 1908-1922.
28. Sun, Y.; Savanenin, A.; Reddy, P.H.; Liu, Y.F. Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D- aspartate receptors via post-synaptic density 95. J. Biol. Chem., 2001, 276, 24713-24718.
29. Fernandes, H.B.; Baimbridge, K.G.; Church, J.; Hayden, M.R.; Raymond, L.A. Mitochondrial sensitivity and altered calcium handling underlie enhanced NMDA-induced apoptosis in YAC128 model of Huntington's disease. J. Neurosci., 2007, 27, 13614-13623.
30. Beister, A.; Kraus, P.; Kuhn, W.; Dose, M.; Weindl, A.; Gerlach, M. The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease. J. Neural Transm. Suppl., 2004, (68), 117-122.
31. Beal, M.F.; Kowall, N.W.; Swartz, K.J.; Ferrante, R.J.; Martin, J.B. Systemic approaches to modifying quinolinic acid striatal lesions in rats. J. Neurosci., 1988, 8, 3901-3908.
32. Cleveland, D.W.; Rothstein, J.D. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat. Rev. Neurosci., 2001, 2, 806-819.
33. Kruman, II; Pedersen, W.A.; Springer, J.E.; Mattson, M.P. ALS- linked Cu/Zn-SOD mutation increases vulnerability of motor neurons to excitotoxicity by a mechanism involving increased oxidative stress and perturbed calcium homeostasis. Exp. Neurol., 1999, 160, 28-39.
34. Kawahara, Y.; Kwak, S. Excitotoxicity and ALS: what is unique about the AMPA receptors expressed on spinal motor neurons? Amyotroph. Lateral Scler. Other Motor Neuron Disord., 2005, 6, 131-144.
35. Bhatt, J.M.; Gordon, P.H. Current clinical trials in amyotrophic lateral sclerosis. Expert Opin. Investig. Drugs, 2007, 16, 1197-1207.
36. Mattson, M.P.; Kroemer, G. Mitochondria in cell death: novel targets for neuroprotection and cardioprotection. Trends Mol. Med., 2003, 9, 196-205.
37. Galluzzi, L.; Blomgren, K.; Kroemer, G. Mitochondrial membrane permeabilization in neuronal injury. Nat. Rev. Neurosci., 2009, 10, 481-494.
38. Ferri, K.F.; Kroemer, G. Organelle-specific initiation of cell death pathways. Nat. Cell Biol., 2001, 3, E255-E263.
39. Gibson, M.E.; Han, B.H.; Choi, J.; Knudson, C.M.; Korsmeyer, S.J.; Parsadanian, M.; Holtzman, D.M. BAX contributes to apoptotic-like death following neonatal hypoxia-ischemia: evidence for distinct apoptosis pathways. Mol. Med., 2001, 7, 644-655.
40. Tehranian, R.; Rose, M.E.; Vagni, V.; Pickrell, A.M.; Griffith, R.P.; Liu, H.; Clark, R.S.; Dixon, C.E.; Kochanek, P.M.; Graham, S.H. Disruption of Bax protein prevents neuronal cell death but produces cognitive impairment in mice following traumatic brain injury. J. Neurotrauma, 2008, 25, 755-767.
41. Rodrigues, C.M.; Spellman, S.R.; Sola, S.; Grande, A.W.; Linehan-Stieers, C.; Low, W.C.; Steer, C.J. Neuroprotection by a bile acid in an acute stroke model in the rat. J. Cereb. Blood Flow Metab., 2002, 22, 463-471.
42. Rodrigues, C.M.; Sola, S.; Nan, Z.; Castro, R.E.; Ribeiro, P.S.; Low, W.C.; Steer, C.J. Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats. Proc. Natl. Acad. Sci. USA, 2003, 100, 6087-6092.
43. Viana, R.J.; Nunes, A.F.; Castro, R.E.; Ramalho, R.M.; Meyerson, J.; Fossati, S.; Ghiso, J.; Rostagno, A.; Rodrigues, C.M. Tauroursodeoxycholic acid prevents E22Q Alzheimer's Abeta toxicity in human cerebral endothelial cells. Cell Mol. Life Sci., 2009, 66, 1094-1104.
44. Amaral, J.D.; Viana, R.J.; Ramalho, R.M.; Steer, C.J.; Rodrigues, C.M. Bile acids: regulation of apoptosis by ursodeoxycholic acid. J. Lipid Res., 2009, 50, 1721-1734.
45. Friedlander, R.M. Apoptosis and caspases in neurodegenerative diseases. N. Engl. J. Med., 2003, 348, 1365-1375.
46. Gafni, J.; Ellerby, L.M. Calpain activation in Huntington's disease. J. Neurosci., 2002, 22, 4842-4849.
47. Li, M.; Ona, V.O.; Guegan, C.; Chen, M.; Jackson-Lewis, V.; Andrews, L.J.; Olszewski, A.J.; Stieg, P.E.; Lee, J.P.; Przedborski, S.; Friedlander, R.M. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science, 2000, 288, 335-339.
48. Tatton, W.G.; Chalmers-Redman, R.; Brown, D.; Tatton, N. Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann. Neurol., 2003, 53(Suppl 3), S61-S70.
49. Yuan, J.; Yankner, B.A. Apoptosis in the nervous system. Nature, 2000, 407, 802-809.
50. Kroemer, G.; Galluzzi, L.; Brenner, C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev., 2007, 87, 99-163.
51. Culmsee, C.; Mattson, M.P. p53 in neuronal apoptosis. Biochem. Biophys. Res. Commun., 2005, 331, 761-777.
52. Bruckner, S.R.; Perry, G.; Estus, S. 4-hydroxynonenal contributes to NGF withdrawal-induced neuronal apoptosis. J. Neurochem., 2003, 85, 999-1005.
53. Zhou, H.; Li, X.M.; Meinkoth, J.; Pittman, R.N. Akt regulates cell survival and apoptosis at a postmitochondrial level. J. Cell Biol., 2000, 151, 483-494.
54. Cutler, R.G.; Kelly, J.; Storie, K.; Pedersen, W.A.; Tammara, A.; Hatanpaa, K.; Troncoso, J.C.; Mattson, M.P. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2004, 101, 2070-2075.
55. Haughey, N.J.; Cutler, R.G.; Tamara, A.; McArthur, J.C.; Vargas, D.L.; Pardo, C.A.; Turchan, J.; Nath, A.; Mattson, M.P. Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann. Neurol., 2004, 55, 257-267.
56. Cutler, R.G.; Pedersen, W.A.; Camandola, S.; Rothstein, J.D.; Mattson, M.P. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann. Neurol., 2002, 52, 448-457.
57. Corral-Debrinski, M.; Horton, T.; Lott, M.T.; Shoffner, J.M.; Beal, M.F.; Wallace, D.C. Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. Nat. Genet., 1992, 2, 324-329.
58. Lin, M.T.; Beal, M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature, 2006, 443, 787-795.
59. Melov, S. Modeling mitochondrial function in aging neurons. Trends Neurosci., 2004, 27, 601-606.
60. Niwa, K.; Kazama, K.; Younkin, S.G.; Carlson, G.A.; Iadecola, C. Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol. Dis., 2002, 9, 61-68.
61. Lustbader, J.W.; Cirilli, M.; Lin, C.; Xu, H.W.; Takuma, K.; Wang, N.; Caspersen, C.; Chen, X.; Pollak, S.; Chaney, M.; Trinchese, F.; Liu, S.; Gunn-Moore, F.; Lue, L.F.; Walker, D.G.; Kuppusamy, P.; Zewier, Z.L.; Arancio, O.; Stern, D.; Yan, S.S.; Wu, H. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science, 2004, 304, 448-452.
62. Keller, J.N.; Guo, Q.; Holtsberg, F.W.; Bruce-Keller, A.J.; Mattson, M.P. Increased sensitivity to mitochondrial toxin-induced apoptosis in neural cells expressing mutant presenilin-1 is linked to perturbed calcium homeostasis and enhanced oxyradical production. J. Neurosci., 1998, 18, 4439-4450.
63. Guo, Q.; Christakos, S.; Robinson, N.; Mattson, M.P. Calbindin D28k blocks the proapoptotic actions of mutant presenilin 1: reduced oxidative stress and preserved mitochondrial function. Proc. Natl. Acad. Sci. USA, 1998, 95, 3227-3232.
64. Panov, A.V.; Gutekunst, C.A.; Leavitt, B.R.; Hayden, M.R.; Burke, J.R.; Strittmatter, W.J.; Greenamyre, J.T. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci., 2002, 5, 731-736.
65. Trushina, E.; Dyer, R.B.; Badger, J.D., 2nd; Ure, D.; Eide, L.; Tran, D.D.; Vrieze, B.T.; Legendre-Guillemin, V.; McPherson, P.S.; Mandavilli, B.S.; Van Houten, B.; Zeitlin, S.; McNiven, M.; Aebersold, R.; Hayden, M.; Parisi, J.E.; Seeberg, E.; Dragatsis, I.; Doyle, K.; Bender, A.; Chacko, C.; McMurray, C.T. Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol. Cell Biol., 2004, 24, 8195-8209.
66. Manfredi, G.; Xu, Z. Mitochondrial dysfunction and its role in motor neuron degeneration in ALS. Mitochondrion, 2005, 5, 77-87.
67. Tarnopolsky, M.A.; Beal, M.F. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann. Neurol., 2001, 49, 561-574.
68. Mosconi, L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur. J. Nucl. Med. Mol. Imaging, 2005, 32, 486-510.
69. Dagher, A. Functional imaging in Parkinson's disease. Semin. Neurol., 2001, 21, 23-32.
70. Feigin, A.; Leenders, K.L.; Moeller, J.R.; Missimer, J.; Kuenig, G.; Spetsieris, P.; Antonini, A.; Eidelberg, D. Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study. J. Nucl. Med., 2001, 42, 1591-1595.
71. Bubber, P.; Haroutunian, V.; Fisch, G.; Blass, J.P.; Gibson, G.E. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann. Neurol., 2005, 57, 695-703.
72. Smigrodzki, R.; Parks, J.; Parker, W.D. High frequency of mitochondrial complex I mutations in Parkinson's disease and aging. Neurobiol. Aging, 2004, 25, 1273-1281.
73. Bogaerts, V.; Theuns, J.; van Broeckhoven, C. Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria? Genes Brain Behav., 2008, 7, 129-151.
74. Nakagawa, T.; Shimizu, S.; Watanabe, T.; Yamaguchi, O.; Otsu, K.; Yamagata, H.; Inohara, H.; Kubo, T.; Tsujimoto, Y. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature, 2005, 434, 652-658.
75. Mehta, S.L.; Manhas, N.; Raghubir, R. Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res. Rev., 2007, 54, 34-66.
76. Lee, J.; Boo, J.H.; Ryu, H. The failure of mitochondria leads to neurodegeneration: Do mitochondria need a jump start? Adv. Drug Deliv. Rev., 2009, 61, 1316-1323.
77. Ryu, H.; Lee, J.; Impey, S.; Ratan, R.R.; Ferrante, R.J. Antioxidants modulate mitochondrial PKA and increase CREB binding to D-loop DNA of the mitochondrial genome in neurons. Proc. Natl. Acad. Sci. USA, 2005, 102, 13915-13920.
78. Jang, M.H.; Jung, S.B.; Lee, M.H.; Kim, C.J.; Oh, Y.T.; Kang, I.; Kim, J.; Kim, E.H. Melatonin attenuates amyloid beta25-35- induced apoptosis in mouse microglial BV2 cells. Neurosci. Lett., 2005, 380, 26-31.
79. Haridas, V.; Hanausek, M.; Nishimura, G.; Soehnge, H.; Gaikwad, A.; Narog, M.; Spears, E.; Zoltaszek, R.; Walaszek, Z.; Gutterman, J.U. Triterpenoid electrophiles (avicins) activate the innate stress response by redox regulation of a gene battery. J. Clin. Invest., 2004, 113, 65-73.
80. Haridas, V.; Li, X.; Mizumachi, T.; Higuchi, M.; Lemeshko, V.V.; Colombini, M.; Gutterman, J.U. Avicins, a novel plant-derived metabolite lowers energy metabolism in tumor cells by targeting the outer mitochondrial membrane. Mitochondrion, 2007, 7, 234-240.
81. Leo, S.; Szabadkai, G.; Rizzuto, R. The mitochondrial antioxidants MitoE(2) and MitoQ(10) increase mitochondrial Ca(2+) load upon cell stimulation by inhibiting Ca(2+) efflux from the organelle. Ann. NY Acad. Sci., 2008, 1147, 264-274.
82. Wang, X.; Zhu, S.; Drozda, M.; Zhang, W.; Stavrovskaya, I.G.; Cattaneo, E.; Ferrante, R.J.; Kristal, B.S.; Friedlander, R.M. Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc. Natl. Acad. Sci. USA, 2003, 100, 10483-10487.
83. Watson, G.S.; Cholerton, B.A.; Reger, M.A.; Baker, L.D.; Plymate, S.R.; Asthana, S.; Fishel, M.A.; Kulstad, J.J.; Green, P.S.; Cook, D.G.; Kahn, S.E.; Keeling, M.L.; Craft, S. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am. J. Geriatr. Psychiatry, 2005, 13, 950-958.
84. Petri, S.; Kiaei, M.; Damiano, M.; Hiller, A.; Wille, E.; Manfredi, G.; Calingasan, N.Y.; Szeto, H.H.; Beal, M.F. Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. J. Neurochem., 2006, 98, 1141-1148.
85. Yang, L.; Zhao, K.; Calingasan, N.Y.; Luo, G.; Szeto, H.H.; Beal, M.F. Mitochondria targeted peptides protect against 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Antioxid. Redox. Signal., 2009, 11, 2095-2104.
86. Hisatomi, T.; Nakazawa, T.; Noda, K.; Almulki, L.; Miyahara, S.; Nakao, S.; Ito, Y.; She, H.; Kohno, R.; Michaud, N.; Ishibashi, T.; Hafezi-Moghadam, A.; Badley, A.D.; Kroemer, G.; Miller, J.W. HIV protease inhibitors provide neuroprotection through inhibition of mitochondrial apoptosis in mice. J. Clin. Invest., 2008, 118, 2025-2038.
87. Gaedicke, S.; Firat-Geier, E.; Constantiniu, O.; Lucchiari-Hartz, M.; Freudenberg, M.; Galanos, C.; Niedermann, G. Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis. Cancer Res., 2002, 62, 6901-6908.
88. Miller, F.D.; Pozniak, C.D.; Walsh, G.S. Neuronal life and death: an essential role for the p53 family. Cell Death Differ., 2000, 7, 880-888.
89. Lindahl, T. Instability and decay of the primary structure of DNA. Nature, 1993, 362, 709-715.
90. Mullaart, E.; Boerrigter, M.E.; Ravid, R.; Swaab, D.F.; Vijg, J. Increased levels of DNA breaks in cerebral cortex of Alzheimer's disease patients. Neurobiol. Aging, 1990, 11, 169-173.
91. Zhang, J.; Perry, G.; Smith, M.A.; Robertson, D.; Olson, S.J.; Graham, D.G.; Montine, T.J. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am. J. Pathol., 1999, 154, 1423-1429.
92. Bradley, W.G.; Krasin, F. A new hypothesis of the etiology of amyotrophic lateral sclerosis. The DNA hypothesis. Arch. Neurol., 1982, 39, 677-680.
93. Shaikh, A.Y.; Martin, L.J. DNA base-excision repair enzyme apurinic/apyrimidinic endonuclease/redox factor-1 is increased and competent in the brain and spinal cord of individuals with amyotrophic lateral sclerosis. Neuromol. Med., 2002, 2, 47-60.
94. Kastan, M.B.; Lim, D.S. The many substrates and functions of ATM. Nat. Rev. Mol. Cell Biol., 2000, 1, 179-186.
95. Martin, L.J.; Liu, Z.; Pipino, J.; Chestnut, B.; Landek, M.A. Molecular regulation of DNA damage-induced apoptosis in neurons of cerebral cortex. Cereb. Cortex, 2009, 19, 1273-1293.
96. Morrison, R.S.; Kinoshita, Y.; Johnson, M.D.; Guo, W.; Garden, G.A. p53-dependent cell death signaling in neurons. Neurochem. Res., 2003, 28, 15-27.
97. de la Monte, S.M.; Sohn, Y.K.; Ganju, N.; Wands, J.R. P53- and CD95-associated apoptosis in neurodegenerative diseases. Lab. Invest., 1998, 78, 401-411.
98. de la Monte, S.M.; Sohn, Y.K.; Wands, J.R. Correlates of p53- and Fas (CD95)-mediated apoptosis in Alzheimer's disease. J. Neurol. Sci., 1997, 152, 73-83.
99. LaFerla, F.M.; Hall, C.K.; Ngo, L.; Jay, G. Extracellular deposition of beta-amyloid upon p53-dependent neuronal cell death in transgenic mice. J. Clin. Invest., 1996, 98, 1626-1632.
100. Ramalho, R.M.; Ribeiro, P.S.; Sola, S.; Castro, R.E.; Steer, C.J.; Rodrigues, C.M. Inhibition of the E2F-1/p53/Bax pathway by tauroursodeoxycholic acid in amyloid beta-peptide-induced apoptosis of PC12 cells. J. Neurochem., 2004, 90, 567-575.
101. Seidl, R.; Fang-Kircher, S.; Bidmon, B.; Cairns, N.; Lubec, G. Apoptosis-associated proteins p53 and APO-1/Fas (CD95) in brains of adult patients with Down syndrome. Neurosci. Lett., 1999, 260, 9-12.
102. Martin, L.J. p53 is abnormally elevated and active in the CNS of patients with amyotrophic lateral sclerosis. Neurobiol. Dis., 2000, 7, 613-622.
103. Steffan, J.S.; Kazantsev, A.; Spasic-Boskovic, O.; Greenwald, M.; Zhu, Y.Z.; Gohler, H.; Wanker, E.E.; Bates, G.P.; Housman, D.E.; Thompson, L.M. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl. Acad. Sci. USA, 2000, 97, 6763-6768.
104. Hu, Z.; Zeng, L.; Huang, Z.; Zhang, J.; Li, T. The study of Golgi apparatus in Alzheimer's disease. Neurochem. Res., 2007, 32, 1265-1277.
105. Fan, J.; Hu, Z.; Zeng, L.; Lu, W.; Tang, X.; Zhang, J.; Li, T. Golgi apparatus and neurodegenerative diseases. Int. J. Dev. Neurosci., 2008, 26, 523-534.
106. Sesso, A.; Fujiwara, D.T.; Jaeger, M.; Jaeger, R.; Li, T.C.; Monteiro, M.M.; Correa, H.; Ferreira, M.A.; Schumacher, R.I.; Belisario, J.; Kachar, B.; Chen, E.J. Structural elements common to mitosis and apoptosis. Tissue Cell, 1999, 31, 357-371.
107. Mukherjee, S.; Chiu, R.; Leung, S.M.; Shields, D. Fragmentation of the Golgi apparatus: an early apoptotic event independent of the cytoskeleton. Traffic, 2007, 8, 369-378.
108. Mancini, M.; Machamer, C.E.; Roy, S.; Nicholson, D.W.; Thornberry, N.A.; Casciola-Rosen, L.A.; Rosen, A. Caspase-2 is localized at the Golgi complex and cleaves golgin-160 during apoptosis. J. Cell Biol., 2000, 149, 603-612.
109. Walker, A.; Ward, C.; Sheldrake, T.A.; Dransfield, I.; Rossi, A.G.; Pryde, J.G.; Haslett, C. Golgi fragmentation during Fas-mediated apoptosis is associated with the rapid loss of GM130. Biochem. Biophys. Res. Commun., 2004, 316, 6-11.
110. Huynh, D.P.; Yang, H.T.; Vakharia, H.; Nguyen, D.; Pulst, S.M. Expansion of the polyQ repeat in ataxin-2 alters its Golgi localization, disrupts the Golgi complex and causes cell death. Hum. Mol. Genet., 2003, 12, 1485-1496.
111. Karecla, P.I.; Kreis, T.E. Interaction of membranes of the Golgi complex with microtubules in vitro. Eur. J. Cell Biol., 1992, 57, 139-146.
112. Mourelatos, Z.; Gonatas, N.K.; Stieber, A.; Gurney, M.E.; Dal Canto, M.C. The Golgi apparatus of spinal cord motor neurons in transgenic mice expressing mutant Cu,Zn superoxide dismutase becomes fragmented in early, preclinical stages of the disease. Proc. Natl. Acad. Sci. USA, 1996, 93, 5472-5477.
113. Baloyannis, S.J.; Costa, V.; Michmizos, D. Mitochondrial alterations in Alzheimer's disease. Am. J. Alzheimers Dis. Other Demen., 2004, 19, 89-93.
114. Stieber, A.; Chen, Y.; Wei, S.; Mourelatos, Z.; Gonatas, J.; Okamoto, K.; Gonatas, N.K. The fragmented neuronal Golgi apparatus in amyotrophic lateral sclerosis includes the trans-Golgi-network: functional implications. Acta Neuropathol., 1998, 95, 245-253.
115. Sakurai, A.; Okamoto, K.; Fujita, Y.; Nakazato, Y.; Wakabayashi, K.; Takahashi, H.; Gonatas, N.K. Fragmentation of the Golgi apparatus of the ballooned neurons in patients with corticobasal degeneration and Creutzfeldt-Jakob disease. Acta Neuropathol., 2000, 100, 270-274.
116. Sakurai, A.; Okamoto, K.; Yaguchi, M.; Fujita, Y.; Mizuno, Y.; Nakazato, Y.; Gonatas, N.K. Pathology of the inferior olivary nucleus in patients with multiple system atrophy. Acta Neuropathol., 2002, 103, 550-554.
117. Takamine, K.; Okamoto, K.; Fujita, Y.; Sakurai, A.; Takatama, M.; Gonatas, N.K. The involvement of the neuronal Golgi apparatus and trans-Golgi network in the human olivary hypertrophy. J. Neurol. Sci., 2000, 182, 45-50.
118. Fujita, Y.; Ohama, E.; Takatama, M.; Al-Sarraj, S.; Okamoto, K. Fragmentation of Golgi apparatus of nigral neurons with alpha-synuclein-positive inclusions in patients with Parkinson's disease. Acta Neuropathol., 2006, 112, 261-265.
119. Walkley, S.U.; Suzuki, K. Consequences of NPC1 and NPC2 loss of function in mammalian neurons. Biochim. Biophys. Acta, 2004, 1685, 48-62.
120. Stieber, A.; Mourelatos, Z.; Gonatas, N.K. In Alzheimer's disease the Golgi apparatus of a population of neurons without neurofibrillary tangles is fragmented and atrophic. Am. J. Pathol., 1996, 148, 415-426.
121. Diaz-Corrales, F.J.; Asanuma, M.; Miyazaki, I.; Ogawa, N. Rotenone induces disassembly of the Golgi apparatus in the rat dopaminergic neuroblastoma B65 cell line. Neurosci. Lett., 2004, 354, 59-63.
122. Liazoghli, D.; Perreault, S.; Micheva, K.D.; Desjardins, M.; Leclerc, N. Fragmentation of the Golgi apparatus induced by the overexpression of wild-type and mutant human tau forms in neurons. Am. J. Pathol., 2005, 166, 1499-1514.
123. Gomes, C.; Palma, A.S.; Almeida, R.; Regalla, M.; McCluskey, L.F.; Trojanowski, J.Q.; Costa, J. Establishment of a cell model of ALS disease: Golgi apparatus disruption occurs independently from apoptosis. Biotechnol. Lett., 2008, 30, 603-610.
124. De Maria, R.; Lenti, L.; Malisan, F.; d'Agostino, F.; Tomassini, B.; Zeuner, A.; Rippo, M.R.; Testi, R. Requirement for GD3 ganglioside in CD95- and ceramide-induced apoptosis. Science, 1997, 277, 1652-1655.
125. Rippo, M.R.; Malisan, F.; Ravagnan, L.; Tomassini, B.; Condo, I.; Costantini, P.; Susin, S.A.; Rufini, A.; Todaro, M.; Kroemer, G.; Testi, R. GD3 ganglioside directly targets mitochondria in a bcl-2- controlled fashion. FASEB J., 2000, 14, 2047-2054.
126. Lindholm, D.; Wootz, H.; Korhonen, L. ER stress and neurodegenerative diseases. Cell Death Differ., 2006, 13, 385-392.
127. Rao, R.V.; Ellerby, H.M.; Bredesen, D.E. Coupling endoplasmic reticulum stress to the cell death program. Cell Death Differ., 2004, 11, 372-380.
128. Jellinger, K.A. Recent advances in our understanding of neurodegeneration. J. Neural Transm., 2009, 116, 1111-1162.
129. Kim, I.; Xu, W.; Reed, J.C. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat. Rev. Drug Discov., 2008, 7, 1013-1030.
130. Schroder, M.; Kaufman, R.J. ER stress and the unfolded protein response. Mutat Res., 2005, 569, 29-63.
131. Foyouzi-Youssefi, R.; Arnaudeau, S.; Borner, C.; Kelley, W.L.; Tschopp, J.; Lew, D.P.; Demaurex, N.; Krause, K.H. Bcl-2 decreases the free Ca2+ concentration within the endoplasmic reticulum. Proc. Natl. Acad. Sci. USA, 2000, 97, 5723-5728.
132. Jones, R.G.; Bui, T.; White, C.; Madesh, M.; Krawczyk, C.M.; Lindsten, T.; Hawkins, B.J.; Kubek, S.; Frauwirth, K.A.; Wang, Y.L.; Conway, S.J.; Roderick, H.L.; Bootman, M.D.; Shen, H.; Foskett, J.K.; Thompson, C.B. The proapoptotic factors Bax and Bak regulate T Cell proliferation through control of endoplasmic reticulum Ca(2+) homeostasis. Immunity, 2007, 27, 268-280.
133. Oakes, S.A.; Scorrano, L.; Opferman, J.T.; Bassik, M.C.; Nishino, M.; Pozzan, T.; Korsmeyer, S.J. Proapoptotic BAX and BAK regulate the type 1 inositol trisphosphate receptor and calcium leak from the endoplasmic reticulum. Proc. Natl. Acad. Sci. USA, 2005, 102, 105-110.
134. Xu, Q.; Reed, J.C. Bax inhibitor-1, a mammalian apoptosis suppressor identified by functional screening in yeast. Mol. Cell, 1998, 1, 337-346.
135. Ng, F.W.; Nguyen, M.; Kwan, T.; Branton, P.E.; Nicholson, D.W.; Cromlish, J.A.; Shore, G.C. p28 Bap31, a Bcl-2/Bcl-XL- and procaspase-8-associated protein in the endoplasmic reticulum. J. Cell Biol., 1997, 139, 327-338.
136. LaFerla, F.M. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat. Rev. Neurosci., 2002, 3, 862-872.
137. Unterberger, U.; Hoftberger, R.; Gelpi, E.; Flicker, H.; Budka, H.; Voigtlander, T. Endoplasmic reticulum stress features are prominent in Alzheimer disease but not in prion diseases in vivo. J. Neuropathol. Exp. Neurol., 2006, 65, 348-357.
138. Leissring, M.A.; Akbari, Y.; Fanger, C.M.; Cahalan, M.D.; Mattson, M.P.; LaFerla, F.M. Capacitative calcium entry deficits and elevated luminal calcium content in mutant presenilin-1 knockin mice. J. Cell Biol., 2000, 149, 793-798.
139. Levitan, D.; Lee, J.; Song, L.; Manning, R.; Wong, G.; Parker, E.; Zhang, L. PS1 N- and C-terminal fragments form a complex that functions in APP processing and Notch signaling. Proc. Natl. Acad. Sci. USA, 2001, 98, 12186-12190.
140. Terro, F.; Czech, C.; Esclaire, F.; Elyaman, W.; Yardin, C.; Baclet, M.C.; Touchet, N.; Tremp, G.; Pradier, L.; Hugon, J. Neurons overexpressing mutant presenilin-1 are more sensitive to apoptosis induced by endoplasmic reticulum-Golgi stress. J. Neurosci. Res., 2002, 69, 530-539.
141. Katayama, T.; Imaizumi, K.; Sato, N.; Miyoshi, K.; Kudo, T.; Hitomi, J.; Morihara, T.; Yoneda, T.; Gomi, F.; Mori, Y.; Nakano, Y.; Takeda, J.; Tsuda, T.; Itoyama, Y.; Murayama, O.; Takashima, A.; St George-Hyslop, P.; Takeda, M.; Tohyama, M. Presenilin-1 mutations downregulate the signalling pathway of the unfolded-protein response. Nat. Cell Biol., 1999, 1, 479-485.
142. Katayama, T.; Imaizumi, K.; Manabe, T.; Hitomi, J.; Kudo, T.; Tohyama, M. Induction of neuronal death by ER stress in Alzheimer's disease. J. Chem. Neuroanat., 2004, 28, 67-78.
143. Hoozemans, J.J.; Veerhuis, R.; Van Haastert, E.S.; Rozemuller, J.M.; Baas, F.; Eikelenboom, P.; Scheper, W. The unfolded protein response is activated in Alzheimer's disease. Acta Neuropathol., 2005, 110, 165-172.
144. Hoozemans, J.J.; van Haastert, E.S.; Nijholt, D.A.; Rozemuller, A.J.; Eikelenboom, P.; Scheper, W. The unfolded protein response is activated in pretangle neurons in Alzheimer's disease hippocampus. Am. J. Pathol., 2009, 174, 1241-1251.
145. Nakagawa, T.; Zhu, H.; Morishima, N.; Li, E.; Xu, J.; Yankner, B.A.; Yuan, J. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature, 2000, 403, 98-103.
146. Greenamyre, J.T.; Hastings, T.G. Biomedicine. Parkinson's-- divergent causes, convergent mechanisms. Science, 2004, 304, 1120-1122.
147. Imai, Y.; Takahashi, R. How do Parkin mutations result in neurodegeneration? Curr. Opin. Neurobiol., 2004, 14, 384-389.
148. Holtz, W.A.; O'Malley, K.L. Parkinsonian mimetics induce aspects of unfolded protein response in death of dopaminergic neurons. J. Biol. Chem., 2003, 278, 19367-19377.
149. Bruijn, L.I.; Miller, T.M.; Cleveland, D.W. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci., 2004, 27, 723-749.
150. Wootz, H.; Hansson, I.; Korhonen, L.; Napankangas, U.; Lindholm, D. Caspase-12 cleavage and increased oxidative stress during motoneuron degeneration in transgenic mouse model of ALS. Biochem. Biophys. Res. Commun., 2004, 322, 281-286.
151. Tobisawa, S.; Hozumi, Y.; Arawaka, S.; Koyama, S.; Wada, M.; Nagai, M.; Aoki, M.; Itoyama, Y.; Goto, K.; Kato, T. Mutant SOD1 linked to familial amyotrophic lateral sclerosis, but not wild-type SOD1, induces ER stress in COS7 cells and transgenic mice. Biochem. Biophys. Res. Commun., 2003, 303, 496-503.
152. Tang, T.S.; Tu, H.; Chan, E.Y.; Maximov, A.; Wang, Z.; Wellington, C.L.; Hayden, M.R.; Bezprozvanny, I. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron, 2003, 39, 227-239.
153. Lipinski, M.M.; Yuan, J. Mechanisms of cell death in polyglutamine expansion diseases. Curr. Opin. Pharmacol., 2004, 4, 85-90.
154. Nishitoh, H.; Matsuzawa, A.; Tobiume, K.; Saegusa, K.; Takeda, K.; Inoue, K.; Hori, S.; Kakizuka, A.; Ichijo, H. ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats. Genes Dev., 2002, 16, 1345-1355.
155. Kouroku, Y.; Fujita, E.; Jimbo, A.; Kikuchi, T.; Yamagata, T.; Momoi, M.Y.; Kominami, E.; Kuida, K.; Sakamaki, K.; Yonehara, S.; Momoi, T. Polyglutamine aggregates stimulate ER stress signals and caspase-12 activation. Hum. Mol. Genet., 2002, 11, 1505-1515.
156. Boyce, M.; Bryant, K.F.; Jousse, C.; Long, K.; Harding, H.P.; Scheuner, D.; Kaufman, R.J.; Ma, D.; Coen, D.M.; Ron, D.; Yuan, J. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science, 2005, 307, 935-939.
157. Smith, W.W.; Jiang, H.; Pei, Z.; Tanaka, Y.; Morita, H.; Sawa, A.; Dawson, V.L.; Dawson, T.M.; Ross, C.A. Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. Hum. Mol. Genet., 2005, 14, 3801-3811.
158. Reijonen, S.; Putkonen, N.; Norremolle, A.; Lindholm, D.; Korhonen, L. Inhibition of endoplasmic reticulum stress counteracts neuronal cell death and protein aggregation caused by N-terminal mutant huntingtin proteins. Exp. Cell Res., 2008, 314, 950-960.
159. Costa-Mattioli, M.; Gobert, D.; Stern, E.; Gamache, K.; Colina, R.; Cuello, C.; Sossin, W.; Kaufman, R.; Pelletier, J.; Rosenblum, K.; Krnjevic, K.; Lacaille, J.C.; Nader, K.; Sonenberg, N. eIF2alpha phosphorylation bidirectionally regulates the switch from short-to long-term synaptic plasticity and memory. Cell, 2007, 129, 195-206.
160. Nishitoh, H.; Kadowaki, H.; Nagai, A.; Maruyama, T.; Yokota, T.; Fukutomi, H.; Noguchi, T.; Matsuzawa, A.; Takeda, K.; Ichijo, H. ALS-linked mutant SOD1 induces ER stress-and ASK1-dependent motor neuron death by targeting Derlin-1. Genes Dev., 2008, 22, 1451-1464.
161. Kawaguchi, M.; Terai, T.; Utata, R.; Kato, M.; Tsuganezawa, K.; Tanaka, A.; Kojima, H.; Okabe, T.; Nagano, T. Development of a novel fluorescent probe for fluorescence correlation spectroscopic detection of kinase inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 3752-3755.
162. Salh, B. c-Jun N-terminal kinases as potential therapeutic targets. Expert Opin. Ther. Targets, 2007, 11, 1339-1353.
163. Zhang, L.; Yu, J.; Pan, H.; Hu, P.; Hao, Y.; Cai, W.; Zhu, H.; Yu, A.D.; Xie, X.; Ma, D.; Yuan, J. Small molecule regulators of autophagy identified by an image-based high-throughput screen. Proc. Natl. Acad. Sci. USA, 2007, 104, 19023-19028.
164. Sarkar, S.; Perlstein, E.O.; Imarisio, S.; Pineau, S.; Cordenier, A.; Maglathlin, R.L.; Webster, J.A.; Lewis, T.A.; O'Kane, C.J.; Schreiber, S.L.; Rubinsztein, D.C. Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nat. Chem. Biol., 2007, 3, 331-338.
165. Kouroku, Y.; Fujita, E.; Tanida, I.; Ueno, T.; Isoai, A.; Kumagai, H.; Ogawa, S.; Kaufman, R.J.; Kominami, E.; Momoi, T. ER stress (PERK/eIF2alpha phosphorylation) mediates the polyglutamine-induced LC3 conversion, an essential step for autophagy formation. Cell Death Differ., 2007, 14, 230-239.
166. Serradeil-Le Gal, C.; Lacour, C.; Valette, G.; Garcia, G.; Foulon, L.; Galindo, G.; Bankir, L.; Pouzet, B.; Guillon, G.; Barberis, C.; Chicot, D.; Jard, S.; Vilain, P.; Garcia, C.; Marty, E.; Raufaste, D.; Brossard, G.; Nisato, D.; Maffrand, J.P.; Le Fur, G. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J. Clin. Invest., 1996, 98, 2729-2738.
167. Burrows, J.A.; Willis, L.K.; Perlmutter, D.H. Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1- AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. Proc. Natl. Acad. Sci. USA, 2000, 97, 1796-1801.
168. Tamarappoo, B.K.; Verkman, A.S. Defective aquaporin-2 trafficking in nephrogenic diabetes insipidus and correction by chemical chaperones. J. Clin. Invest., 1998, 101, 2257-2267.
169. Conde, C.; Caceres, A. Microtubule assembly, organization and dynamics in axons and dendrites. Nat. Rev. Neurosci., 2009, 10, 319-332.
170. Roy, S.; Zhang, B.; Lee, V.M.; Trojanowski, J.Q. Axonal transport defects: a common theme in neurodegenerative diseases. Acta Neuropathol., 2005, 109, 5-13.
171. Chevalier-Larsen, E.; Holzbaur, E.L. Axonal transport and neurodegenerative disease. Biochim. Biophys. Acta, 2006, 1762, 1094-1108.
172. Hirokawa, N.; Takemura, R. Molecular motors in neuronal development, intracellular transport and diseases. Curr. Opin. Neurobiol., 2004, 14, 564-573.
173. Liu, Q.; Xie, F.; Siedlak, S.L.; Nunomura, A.; Honda, K.; Moreira, P.I.; Zhua, X.; Smith, M.A.; Perry, G. Neurofilament proteins in neurodegenerative diseases. Cell Mol. Life Sci., 2004, 61, 3057-3075.
174. De Vos, K.J.; Grierson, A.J.; Ackerley, S.; Miller, C.C. Role of axonal transport in neurodegenerative diseases. Annu. Rev. Neurosci., 2008, 31, 151-173.
175. Schindowski, K.; Belarbi, K.; Buee, L. Neurotrophic factors in Alzheimer's disease: role of axonal transport. Genes Brain Behav., 2008, 7(Suppl 1), 43-56.
176. Stokin, G.B.; Lillo, C.; Falzone, T.L.; Brusch, R.G.; Rockenstein, E.; Mount, S.L.; Raman, R.; Davies, P.; Masliah, E.; Williams, D.S.; Goldstein, L.S. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science, 2005, 307, 1282-1288.
177. Koo, E.H.; Sisodia, S.S.; Archer, D.R.; Martin, L.J.; Weidemann, A.; Beyreuther, K.; Fischer, P.; Masters, C.L.; Price, D.L. Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport. Proc. Natl. Acad. Sci. USA, 1990, 87, 1561-1565.
178. Kamal, A.; Almenar-Queralt, A.; LeBlanc, J.F.; Roberts, E.A.; Goldstein, L.S. Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP. Nature, 2001, 414, 643-648.
179. Gunawardena, S.; Goldstein, L.S. Cargo-carrying motor vehicles on the neuronal highway: transport pathways and neurodegenerative disease. J. Neurobiol., 2004, 58, 258-271.
180. Takashima, A.; Murayama, M.; Murayama, O.; Kohno, T.; Honda, T.; Yasutake, K.; Nihonmatsu, N.; Mercken, M.; Yamaguchi, H.; Sugihara, S.; Wolozin, B. Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau. Proc. Natl. Acad. Sci. USA, 1998, 95, 9637-9641.
181. Morfini, G.; Szebenyi, G.; Elluru, R.; Ratner, N.; Brady, S.T. Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility. EMBO J., 2002, 21, 281-293.
182. Pigino, G.; Morfini, G.; Atagi, Y.; Deshpande, A.; Yu, C.; Jungbauer, L.; LaDu, M.; Busciglio, J.; Brady, S. Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid beta. Proc. Natl. Acad. Sci. USA, 2009, 106, 5907-5912.
183. Ishihara, T.; Hong, M.; Zhang, B.; Nakagawa, Y.; Lee, M.K.; Trojanowski, J.Q.; Lee, V.M. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron, 1999, 24, 751-762.
184. Zhang, B.; Maiti, A.; Shively, S.; Lakhani, F.; McDonald-Jones, G.; Bruce, J.; Lee, E.B.; Xie, S.X.; Joyce, S.; Li, C.; Toleikis, P.M.; Lee, V.M.; Trojanowski, J.Q. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc. Natl. Acad. Sci. USA, 2005, 102, 227-231.
185. Hong, M.; Zhukareva, V.; Vogelsberg-Ragaglia, V.; Wszolek, Z.; Reed, L.; Miller, B.I.; Geschwind, D.H.; Bird, T.D.; McKeel, D.; Goate, A.; Morris, J.C.; Wilhelmsen, K.C.; Schellenberg, G.D.; Trojanowski, J.Q.; Lee, V.M. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science, 1998, 282, 1914-1917.
186. Tesseur, I.; Van Dorpe, J.; Bruynseels, K.; Bronfman, F.; Sciot, R.; Van Lommel, A.; Van Leuven, F. Prominent axonopathy and disruption of axonal transport in transgenic mice expressing human apolipoprotein E4 in neurons of brain and spinal cord. Am. J. Pathol., 2000, 157, 1495-1510.
187. Verhey, K.J.; Meyer, D.; Deehan, R.; Blenis, J.; Schnapp, B.J.; Rapoport, T.A.; Margolis, B. Cargo of kinesin identified as JIP scaffolding proteins and associated signaling molecules. J. Cell Biol., 2001, 152, 959-970.
188. Norris, E.H.; Giasson, B.I.; Lee, V.M. Alpha-synuclein: normal function and role in neurodegenerative diseases. Curr. Top. Dev. Biol., 2004, 60, 17-54.
189. Jensen, P.H.; Nielsen, M.S.; Jakes, R.; Dotti, C.G.; Goedert, M. Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J. Biol. Chem., 1998, 273, 26292-26294.
190. Murphy, D.D.; Rueter, S.M.; Trojanowski, J.Q.; Lee, V.M. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci., 2000, 20, 3214-3220.
191. Li, W.; Hoffman, P.N.; Stirling, W.; Price, D.L.; Lee, M.K. Axonal transport of human alpha-synuclein slows with aging but is not affected by familial Parkinson's disease-linked mutations. J. Neurochem., 2004, 88, 401-410.
192. Gil, J.M.; Rego, A.C. Mechanisms of neurodegeneration in Huntington's disease. Eur. J. Neurosci., 2008, 27, 2803-2820.
193. Gauthier, L.R.; Charrin, B.C.; Borrell-Pages, M.; Dompierre, J.P.; Rangone, H.; Cordelieres, F.P.; De Mey, J.; MacDonald, M.E.; Lessmann, V.; Humbert, S.; Saudou, F. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell, 2004, 118, 127-138.
194. Szebenyi, G.; Morfini, G.A.; Babcock, A.; Gould, M.; Selkoe, K.; Stenoien, D.L.; Young, M.; Faber, P.W.; MacDonald, M.E.; McPhaul, M.J.; Brady, S.T. Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport. Neuron, 2003, 40, 41-52.
195. Gunawardena, S.; Goldstein, L.S. Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila. Neuron, 2001, 32, 389-401.
196. Zhang, B.; Tu, P.; Abtahian, F.; Trojanowski, J.Q.; Lee, V.M. Neurofilaments and orthograde transport are reduced in ventral root axons of transgenic mice that express human SOD1 with a G93A mutation. J. Cell Biol., 1997, 139, 1307-1315.
197. Williamson, T.L.; Cleveland, D.W. Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. Nat. Neurosci., 1999, 2, 50-56.
198. Rothstein, J.D. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann. Neurol., 2009, 65(Suppl 1), S3- S9.
199. Engel, T.; Goni-Oliver, P.; Gomez de Barreda, E.; Lucas, J.J.; Hernandez, F.; Avila, J. Lithium, a potential protective drug in Alzheimer's disease. Neurodegener. Dis., 2008, 5, 247-249.
200. Kimura, T.; Yamashita, S.; Nakao, S.; Park, J.M.; Murayama, M.; Mizoroki, T.; Yoshiike, Y.; Sahara, N.; Takashima, A. GSK-3beta is required for memory reconsolidation in adult brain. PLoS One, 2008, 3, e3540.